View source version on businesswire.com: https://www.businesswire.com/news/home/20260324619113/en/ The articles, information, and content displayed on this webpage ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the exercise of 35,059,448 warrants, which were ...

The CNPV designation provides the company with enhanced regulatory communication and a significantly shortened review ...

Compass Pathways is already in the final stage of development on a psychedelic medicine to treat depression.

Compass Pathways PLC (NASDAQ:CMPS) is among the best psychedelic stocks to buy in 2026. Its flagship psychedelic drug candidate COMP360 is aimed at treating patients with depression. COMP360 uses a ...

It's been a long road for Compass Pathways (NASDAQ: CMPS) to prove that its treatment using psilocybin therapy for treatment-resistant depression (TRD) can be successful. It was back in 2018 when the ...

View source version on businesswire.com: https://www.businesswire.com/news/home/20260324619113/en/ ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.